premenopausal

Related by string. pre menopausal . Premenopausal * * premenopausal women . premenopausal breast cancer . Premenopausal Women . develop premenopausal breast . Premenopausal women *

Related by context. All words. (Click for frequent words.) 74 postmenopausal 71 pre menopausal 70 oophorectomy 69 premenopausal women 66 premenopausal breast cancer 66 postmenopausal women 66 perimenopausal women 66 estrogen receptor negative 66 undergone hysterectomy 65 osteopenic 64 vertebral fracture 64 post menopausal 64 parous women 64 subclinical hypothyroidism 64 hip BMD 64 lipid lowering therapy 64 serum testosterone 64 normotensive 63 tibolone 63 postmenopause 63 perimenopausal 63 nondepressed 63 BRCA mutation 63 BRCA2 mutation carriers 63 estrogen therapy 63 MetS 63 irregular menstrual cycles 63 atypical hyperplasia 62 adenoma 62 nulliparous women 62 invasive breast cancer 62 advanced adenoma 62 hypogonadal men 62 polycystic ovary syndrome PCOS 62 hormone therapy estrogen 62 mild gestational diabetes 62 endometrial hyperplasia 62 serum IGF 62 hypogonadal 62 BRCA1 mutations 62 folate intake 62 colorectal adenoma 62 tamoxifen therapy 61 endometrial cancer 61 BRCA2 mutations 61 GnRH agonists 61 epithelial ovarian cancer 61 undergone hysterectomies 61 LNG IUS 61 thyroid hormone levels 61 abnormal mammogram 61 cognitively normal 61 spontaneous preterm birth 61 nondiabetic 61 recurrent VTE 61 hormone therapy 60 androgen deprivation 60 lobular breast cancer 60 nonvertebral fracture 60 postmenopausal hormones 60 femoral neck BMD 60 thyrotropin levels 60 underwent CABG 60 endometrial carcinoma 60 pCR 60 serum estradiol 60 postmenopausal breast cancer 60 BRCA mutations 60 advanced adenomas 60 preterm deliveries 60 dietary calcium intake 60 virologic failure 60 breast carcinoma 60 hsCRP levels 60 beta blocker therapy 60 polycystic ovary syndrome 60 lobular cancer 60 CC genotype 60 recurrent UTI 60 nonobese 60 adrenal function 60 ovarian function 60 hydroxyvitamin D levels 60 colorectal adenomas 60 hormonal therapy 60 prostate cancer CaP 59 bilateral oophorectomy 59 testosterone supplementation 59 iron deficient 59 mineral density 59 nonpregnant women 59 ductal breast cancer 59 systolic BP 59 telomere lengths 59 spontaneous preterm delivery 59 endogenous estrogen 59 luteal phase 59 pathologic fractures 59 prehypertensive 59 underwent bariatric surgery 59 elevated LDL cholesterol 59 TT genotype 59 calcium supplementation 59 DEXA scan 59 BRCA1 mutation carriers 59 serum vitamin D 59 vasomotor symptoms 59 polyp recurrence 59 postmenopausal estrogen 59 menopausal hormone therapy 59 menopausal 59 CARDIA 59 elevated CRP 59 postmenopausal hormone therapy 59 mammographic density 59 amenorrhea 59 hypertensives 59 Dietary Modification Trial 59 postmenopausal hormone 59 CLA supplementation 59 NATRECOR R 59 AVODART 59 estrogen progestin therapy 59 lipid lowering medications 59 serum creatinine levels 59 Health Initiative Observational 59 exemestane 59 hirsutism 59 plasma folate 59 retrospective cohort 59 colorectal neoplasia 59 T1DM 59 CVD mortality 59 abnormal Pap test 59 biochemical relapse 59 serum uric acid 59 subclinical hyperthyroidism 59 endometriosis ovarian cysts 58 cardiovascular mortality 58 carotid stenosis 58 ovulatory cycles 58 Digital Mammographic Imaging 58 autoantibody positive 58 ALND 58 nonvertebral fractures 58 PREMPRO 58 serum PSA 58 undergone radical prostatectomy 58 poor metabolizers 58 adenoma recurrence 58 hormone receptor negative 58 folate supplementation 58 adenomatous polyps 58 asymptomatic carotid stenosis 58 radical nephrectomy 58 conjugated equine estrogen 58 atypia 58 serum phosphate 58 serum calcium levels 58 aromatase inhibitor therapy 58 HbA1c levels 58 hormone receptor positive 58 depressive symptoms 58 T2DM 58 elevated depressive symptoms 58 undergoing radical prostatectomy 58 BRCA gene mutations 58 anovulatory infertility 58 serum selenium 58 postoperative AF 58 salpingo oophorectomy 58 carotid IMT 58 MMSE scores 58 epithelial ovarian 58 aromatase inhibitor 58 tamoxifen 58 preoperative chemotherapy 58 adjuvant radiation 58 folic acid supplement 58 proliferative diabetic retinopathy 58 symptomatic fibroids 58 osteopenia 58 squamous histology 58 NPH insulin 58 lumbar spine BMD 58 biochemical recurrence 58 atypical ductal hyperplasia 58 elevated LDH 58 tumor histology 58 uncomplicated pregnancies 58 ovariectomy 58 breast cancer recurrence 58 baseline HbA1c 58 bone mineral 58 axillary lymph nodes 58 estradiol 58 estrogen receptor positive 58 euthyroid 58 fasting triglyceride levels 58 flutamide 58 postoperative mortality 58 neurocognitive function 58 overt hypothyroidism 57 BENICAR HCT 57 coronary artery calcification 57 Heavy menstrual bleeding 57 definite stent thrombosis 57 neurodevelopmental outcomes 57 antihypertensive therapy 57 primary ovarian insufficiency 57 serum testosterone levels 57 fasting glucose levels 57 advanced neoplasia 57 SHBG levels 57 paclitaxel eluting stents 57 vitamin D supplementation 57 oestradiol 57 operable breast cancer 57 singleton pregnancies 57 Adjuvant chemotherapy 57 fragility fracture 57 relapsed MM 57 APOE e4 57 NSTE ACS 57 BMI percentile 57 breast tenderness 57 premature menopause 57 BRCA mutation carriers 57 osteoporotic 57 histologically confirmed 57 β blockers 57 desvenlafaxine succinate 57 intravenous bisphosphonates 57 APTIVUS r 57 pre eclamptic 57 thiazide diuretics 57 Subgroup analyzes 57 lipid lowering drugs 57 osteoporotic fracture 57 adjuvant therapy 57 slow metabolizers 57 transferrin saturation 57 polycystic ovarian syndrome PCOS 57 highest tertile 57 pancreatic adenocarcinoma 57 haemorrhagic stroke 57 fasting insulin 57 gestational diabetes mellitus GDM 57 subtrochanteric 57 menopause 57 screening colonoscopy 57 adenomas 57 moderate renal impairment 57 ovaries removed 57 colorectal cancer incidence 57 axillary node dissection 57 amenorrhoea 57 gestational hypertension 57 ductal cancer 57 NHANES III 57 lymph node involvement 57 endometrial cancers 57 CYP#D# genotype 57 plasma homocysteine 57 loop diuretics 57 CARDIA study 57 GnRH agonist 57 conjugated equine estrogens 57 vaginal atrophy 57 menstrual bleeding 57 N telopeptide 57 multivariable adjusted 57 impaired fasting glucose 57 benign breast 57 thromboembolic events 56 prophylactic mastectomy 56 basal cell nevus syndrome 56 HIV uninfected 56 serum concentrations 56 glandular tissue 56 sentinel node biopsy 56 sUA 56 breastfed infants 56 VLBW infants 56 androgen excess 56 recurrent atrial fibrillation 56 confounding variables 56 antihypertensive medications 56 neurodevelopmental impairment 56 gallstone disease 56 #mg/dL [001] 56 HNSCC 56 adjuvant hormonal therapy 56 BRCA2 carriers 56 hypocaloric diet 56 ovarian hormones 56 endometrial thickness 56 menarche 56 colon polyps 56 endometrial 56 confidence interval #.#-#.# 56 highest quintile 56 coronary calcification 56 estrogen 56 transaminase levels 56 menopausal symptoms 56 PSADT 56 elevated serum creatinine 56 nondemented 56 colorectal neoplasms 56 androgen deficiency 56 psychiatric comorbidities 56 Prostate Lung Colorectal 56 cervical lesions 56 undergo bariatric surgery 56 prescribed statins 56 arterial thickening 56 postnatally 56 APOE genotype 56 prostate cancer PCa 56 Subgroup analysis 56 perimenopause 56 hematopoietic cancers 56 uterine cancers 56 serum lipid levels 56 testicular tumors 56 ejection fractions 56 metabolically healthy 56 NNRTI resistance 56 GSTT1 56 nonfasting triglyceride levels 56 poorer prognosis 56 adiponectin levels 56 HER2 expression 56 liver transplant recipients 56 parous 56 GH deficient 56 REYATAZ r arm 56 menopausal symptom 56 A1c levels 56 hydroxyvitamin D 56 screening mammogram 56 prepregnancy BMI 56 adjuvant chemotherapy 56 ELBW infants 56 invasive carcinoma 56 postintervention 56 severe renal impairment 56 anastrozole 56 CYPHER Stent 56 hormone estradiol 56 comorbid conditions 56 #mg/day [001] 56 thyroid stimulating hormone 56 nonmelanoma skin cancers 56 urinary albumin 56 ovulation induction 56 cranial irradiation 56 PASI scores 56 letrozole 56 MMSE score 56 #.#ng/ml 56 hemoglobin A1c levels 56 androgen suppression therapy 56 baseline mammogram 56 multivariate analyzes 56 aromatase inhibitors AIs 56 androgen suppression 56 subclinical atherosclerosis 56 preintervention 56 nulliparous 56 cerebral microbleeds 56 KRAS mutations 56 TEAEs 56 isolated systolic hypertension 56 teriparatide 56 contralateral breast cancer 56 Prehypertension 56 vertebral fractures 56 creatinine clearance 56 serum folate 56 hypothalamic amenorrhea 56 hypothyroid 56 leiomyomas 56 beta carotene supplementation 56 CHD mortality 55 nonfatal MI 55 nondiabetic patients 55 benign proliferative breast 55 mIU L 55 valproate 55 medically inoperable 55 adjuvant radiotherapy 55 recurrent miscarriage 55 lowest tertile 55 Screening Trial DMIST 55 gestational diabetes mellitus 55 intima media thickness 55 plasma homocysteine levels 55 invasive ductal breast cancer 55 ALT flares 55 Kaplan Meier analysis 55 PSA velocity 55 nadroparin 55 colorectal polyp 55 hip fracture 55 microbleeds 55 statistically nonsignificant 55 Young Adults CARDIA 55 Calcium intake 55 premenopause 55 dietary questionnaires 55 undergoing hysterectomy 55 hormone therapy HT 55 obese postmenopausal 55 neoadjuvant 55 lignan intake 55 noncarriers 55 dose ionizing radiation 55 tanned indoors 55 statin therapy 55 fibroids endometriosis 55 CLBP 55 chronic prostatitis 55 colorectal liver metastases 55 irregular menses 55 mg/m2 dose 55 Postmenopausal 55 Framingham Offspring Study 55 born preterm 55 estrogen receptor ER 55 magnesium intake 55 KRAS mutations occur 55 hormones progesterone 55 bowel polyps 55 severe menopausal symptoms 55 EBRT 55 axillary lymph node dissection 55 endarterectomy 55 insulin detemir 55 prognostic factors 55 atherogenic dyslipidemia 55 HGPIN 55 serous ovarian cancer 55 cilostazol 55 HER2 positive cancers 55 prolactin levels 55 antioxidant supplementation 55 LHRH receptor positive 55 Schaffir 55 alendronate 55 cystectomy 55 gastrectomy 55 HbA1C levels 55 prophylactic mastectomies 55 FOLFOX4 55 progestins 55 prepregnancy 55 ximelagatran 55 venous thrombosis 55 symptomatic intracerebral hemorrhage 55 proliferative retinopathy 55 tertiles 55 hyperintense lesions 55 varicocele 55 BMD measurements 55 severe periodontitis 55 thyroid nodules 55 NMIBC 55 elevated hsCRP 55 evaluable 55 patients undergoing CABG 55 deep venous thromboses 55 corticosteroid dose 55 prepubertal 55 serum cholesterol 55 eribulin 55 intestinal polyps 55 coronary revascularization 55 dysfunctional voiding 55 preventive mastectomies 55 multivariate logistic regression 55 chorioamnionitis 55 thyroxine 55 antiretroviral naive 55 singleton pregnancy 55 baseline A1C 55 anti HBs 55 dutasteride 55 HF ACTION 55 underwent coronary angiography 55 axillary dissection 55 covariates 55 % CI #.#-#.# [003] 55 adiponectin concentrations 55 colorectal polyps 55 estrogen deficiency 55 contralateral breast 55 HER2 negative 55 mammary tumors 55 stable angina 55 ATACAND 55 bisphosphonate therapy 55 progesterone receptor negative 55 ASCUS 55 Baseline characteristics 55 macroalbuminuria 55 virological failure 55 fasting plasma glucose 55 glucose intolerance 55 binary restenosis 55 malignant polyps 55 solifenacin 55 pre cancerous polyps 55 tertile 55 HER2 positive metastatic breast 55 ng ml 55 unstable angina UA 55 neoadjuvant chemotherapy 55 distal colon cancer 55 dapagliflozin plus 55 elevated triglyceride levels 55 lymph node removal 55 localized prostate cancer 55 habitual snoring 55 obese adolescents 55 breast cancers 55 potential confounders 55 EXJADE 55 comorbid illnesses 55 antidiabetic medications 55 LYSTEDA 55 Ovary removal 55 cerebral infarction 55 sedentary postmenopausal 55 diastolic BP 55 androgen deprivation therapy 55 warfarin therapy 55 lifetime abstainers 55 prospective cohort 55 multivariate adjustment 55 carotid endarterectomy 55 PCa 55 sentinel lymph node biopsy 55 surgically induced 55 BRCA2 mutation 55 baseline LDH 54 fasting glucose 54 untreated AML 54 HBeAg 54 lipid lowering agents 54 underwent radical prostatectomy 54 epidural analgesia 54 antiandrogen 54 DAS# scores 54 paroxysmal AF 54 glucose intolerant 54 vulvovaginal atrophy 54 precancerous cervical lesions 54 dyspareunia 54 repigmentation 54 glycated hemoglobin levels 54 screening mammography 54 umol L 54 mammographic breast density 54 progestogen 54 multivariate Cox 54 limiting generalizability 54 albumin excretion 54 metastatic lung cancer 54 mg kg dose 54 adjunctive ABILIFY 54 strontium ranelate 54 ZOLINZA 54 Baltimore Longitudinal Study 54 hamartoma 54 serum urate 54 invasive lobular carcinoma 54 potential confounding variables 54 naturally occurring estrogen 54 RLS symptoms 54 affective psychoses 54 mutated K ras 54 zoledronic acid 54 perioperative complications 54 distant metastases 54 BYSTOLIC 54 LUTS 54 abdominal adiposity 54 renal dysfunction 54 prednisone prednisolone 54 Complication rates 54 recurrent venous thromboembolism 54 hydroxymethyl coenzyme 54 DMIST 54 LV dysfunction 54 sociodemographic characteristics 54 coronary artery calcium 54 evaluable subjects 54 lamotrigine 54 DMPA 54 breastfed exclusively 54 eptifibatide 54 ng dL 54 lumbar spine bone 54 oral antidiabetic medication 54 HBeAg positive patients 54 systemic corticosteroid 54 aged ≥ 54 BRCA gene mutation 54 retrospective cohort study 54 bone resorption 54 white matter hyperintensities 54 vaginal estrogen 54 EGFR mutations 54 hemodialysis patients 54 Hashimoto thyroiditis 54 antidepressant therapy 54 paricalcitol 54 hyperplasia BPH 54 Postmenopausal Women 54 IV bisphosphonates 54 plasma uric acid 54 plus medroxyprogesterone acetate 54 phytoestrogen intake 54 knee osteoarthritis 54 hs CRP 54 virologic response 54 fluvastatin 54 HBeAg positive 54 primary hypercholesterolemia 54 FASLODEX 54 depot medroxyprogesterone acetate 54 DXA scan 54 aminotransferases 54 estrogen metabolites 54 ovulatory infertility 54 curative resection 54 colon polyp 54 pyridostigmine 54 preoperative radiotherapy 54 mCRC patients 54 neutrophil counts 54 atrophic gastritis 54 ovarian carcinoma 54 bone density 54 genistein 54 artery calcification 54 varicoceles 54 adnexal mass 54 breast conserving 54 noncardiovascular mortality 54 HIV seronegative 54 renal cell carcinomas 54 calcium intakes 54 lymphocytosis 54 transfusion syndrome 54 troponin T 54 ischemic strokes 54 chlorthalidone 54 recurrent ovarian 54 nonmelanoma skin cancer 54 virological response 54 specific antigen PSA 54 elevated ALT 54 Insulin sensitivity 54 vicriviroc 54 microalbuminuria 54 NP CRNs 54 oxycodone CR 54 Screening Trial 54 ticlopidine 54 faulty BRCA2 gene 54 bisphosphonate 54 hormone receptor status 54 metastatic RCC 54 timepoint 54 preterm delivery 54 asymptomatic hypothyroidism 54 multiple gestations 54 ARB telmisartan 54 thromboembolic 54 aminotransferase levels 54 abnormal mammograms 54 CR nPR 54 PSA nadir 54 cardiorespiratory fitness 54 undetectable viral load 54 autonomic dysfunction 54 prostates removed 54 d4T 54 hemoglobin A1c HbA1c 54 sociodemographic factors 54 urolithiasis 54 urinary symptoms 54 multivariable analysis 54 creatinine levels 54 premenstrual dysphoric disorder PMDD 54 nmol L 54 spine fractures 54 multiple logistic regression 54 corticosteroid therapy 54 antidiabetic medication 54 nonischemic 54 thyrotropin 54 EDSS scores 54 severe psoriasis 54 typical antipsychotics 54 histological subtype 54 posttreatment 54 serum calcium 54 placebo dexamethasone 54 heavy menstrual bleeding 54 hemorrhagic strokes 54 selenium intake 54 Premenopausal women 54 dysmenorrhea 54 GH deficiency 54 soy isoflavones 54 OADs 54 aspirin therapy 54 narcolepsy cataplexy 54 HbA 1c levels 54 underwent resection 54 steroid dexamethasone 54 RBC folate 54 SIDS infants 54 lobular involution 54 rosuvastatin #mg 54 rCBF 54 nonmetastatic 54 hormonal treatments 54 glargine 54 μmol L 54 benazepril 54 Radical prostatectomy 54 atypical fractures 54 underwent prostatectomy 54 CrCl 54 MELD scores 54 thromboembolism 54 clodronate 54 mcg albinterferon alfa 2b 54 thrombocytopenic 54 HbA 1c 54 heavily pretreated 54 peritoneal cancer 54 comorbidities 54 adenocarcinomas 54 histologic subtype 54 carotid plaque 54 vaginal progesterone gel 54 ventricular enlargement 54 aspartate aminotransferase AST 54 QTc prolongation 54 DHA supplementation 54 PLX STROKE targeting 54 euthymic 54 luteal 54 undergo lumpectomy 54 ovaries surgically 54 postmenopausal osteoporotic women 54 mycophenolate mofetil 54 antiandrogens 54 Wistar rats 54 dose aspirin 54 carbohydrate intolerance 54 dacarbazine chemotherapy 54 adefovir 54 peri menopausal 54 mL/min/#.# m 2 54 induce ovulation 54 onset diabetes mellitus 53 nonfasting triglycerides 53 BARACLUDE 53 undergoing bariatric surgery 53 hippocampal volume 53 bilirubin levels 53 SLNB 53 IFN beta 53 alteplase 53 KRAS status 53 vulvar pain 53 intact parathyroid hormone 53 anovulation 53 dehydroepiandrosterone sulfate 53 penetrance 53 del 5q MDS 53 hydroxychloroquine 53 Netherlands Cohort Study 53 HER2 overexpression 53 CIN3 53 CP CPPS 53 HIV HCV coinfected 53 coronary calcium 53 tryptophan depletion 53 dietary intakes 53 undergoing androgen deprivation 53 subgroup analyzes 53 pattern baldness 53 telomere length 53 bioavailable testosterone 53 NATRECOR ® 53 handgrip strength 53 primary generalized tonic 53 menses 53 breast endometrial 53 glomerular filtration rate 53 suicide attempters 53 univariate 53 microscopic hematuria 53 gestational diabetes 53 LEXIVA r 53 decitabine 53 glycemic diet 53 albuminuria 53 serum GGT 53 oral contraceptive pills 53 reperfusion therapy 53 bilateral prophylactic mastectomy 53 risedronate 53 ovary removal 53 Osteopenia 53 abnormal cytology 53 mg Proellex 53 metabolic syndrome MetS 53 carotid atherosclerosis 53 serum urate levels 53 macrovascular 53 SORT OUT III 53 ApoE4 53 oral bisphosphonates 53 aldosterone antagonist 53 minimally symptomatic 53 selenium supplementation 53 undetectable HBV DNA 53 chemoradiation 53 abnormal glucose tolerance 53 de novo AML 53 PREZISTA r 53 VADT 53 Cesarean deliveries 53 tHcy 53 urate levels 53 systemic lupus erythematosus SLE 53 venlafaxine Effexor 53 Vagifem 53 systolic hypertension 53 nonresponders 53 Venous thromboembolism 53 deCODE BreastCancer TM 53 Sexual dysfunction 53 urinary N telopeptide 53 abdominal hysterectomy 53 phytoestrogen 53 HYVET 53 detrusor overactivity 53 peri menopausal women 53 DAPT 53 homocysteine concentrations 53 sociodemographic 53 % CI #.#-#.# [006] 53 follicular phase 53 medroxyprogesterone acetate 53 placental malaria 53 premenstrual syndrome PMS 53 hemoglobin concentration 53 HER2 positive tumors 53 RBP4 levels 53 QTc 53 trastuzumab 53 breast tissue 53 invasive lobular 53 mg d 53 precocious puberty 53 papillary renal cell carcinoma 53 azoospermia 53 ziprasidone 53 prospective longitudinal 53 Hb A1C 53 tamsulosin 53 leptin deficient mice 53 proteinuria 53 #q#.# deletion syndrome 53 neoadjuvant therapy 53 recurrent glioblastoma multiforme 53 vitamin D deficient 53 estrogen hormone therapy 53 RRMS patients 53 thyroidectomy 53 triiodothyronine 53 mg BID 53 CAVEATS 53 extrapyramidal symptoms 53 XELOX 53 hyperandrogenism 53 partial nephrectomy 53 dosing cohort 53 progestin therapy 53 myocardial infarction MI 53 menthol smokers 53 TAXUS Express Stent 53 Flu Cy 53 substudy 53 serum phosphorous 53 antihypertensive drugs 53 ARIXTRA 53 coronary blockages 53 glioma tumors 53 serum ferritin 53 XIENCE V demonstrated 53 liver biopsies 53 colon tumors 53 histologically 53 antiestrogens 53 insulin glargine 53 C#BL/#J mice 53 asymptomatic 53 lobular carcinoma 53 Ophena 53 osteosarcomas 53 thrombophilia 53 depressive symptomatology 53 tHcy concentrations 53 calcium metabolism 53 #mmHg [001] 53 hypogonadotropic hypogonadism 53 metastatic renal cell carcinoma 53 underwent surgical resection 53 dysglycemia 53 hMG 53 lispro 53 teratogenic 53 Invasive Breast Cancer 53 serum sodium 53 acrylamide intake 53 subfertility 53 Depressive symptoms 53 ER CHOP 53 cognitive impairment 53 BMI ≥ 53 androgenic hormones 53 VaD 53 situ LCIS 53 tenofovir emtricitabine 53 ginkgo biloba extract 53 cTnT 53 metastatic HRPC 53 fetal malformations 53 Hypoactive Sexual Desire Disorder 53 brain shrinkage 53 urinary tract symptoms LUTS 53 urinary calcium 53 colon rectal 53 systolic blood pressure 53 Wactawski Wende 53 bowel resection 53 nodal metastases 53 pravastatin therapy 53 AGILECT R 53 APOE ε4 53 DMARD 53 squamous cell lung cancer 53 hippocampal volumes 53 hypercholesterolaemia 53 neurodevelopmental outcome 53 hamartomas 53 prescribe statins 53 bezafibrate 53 hypercholesterolemic patients 53 multivariate analysis 53 serum folate concentrations 53 ductal carcinomas 53 hepatic function 53 HBeAg negative 53 sulphonylureas 53 undergo prostate biopsy 53 L thyroxine 53 transaminase elevations 53 MS relapses 53 colorectal cancer 53 prospectively stratified 53 Caesarean deliveries 53 randomized 53 DEXA scans 53 antiangiogenic therapy 53 acetabular dysplasia 53 APOE e4 gene 53 periprocedural MI 53 vaginal hysterectomy 53 valacyclovir 53 Ophena TM 53 thrombolytic therapy 53 lanthanum carbonate 53 thromboembolic disease 53 THIS STUDY 53 colorectal carcinoma 53 cancerous breast 53 longitudinal cohort study

Back to home page